He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy. Since 2003, Dr. Di Leo has served as Head of the Sandro Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy.